Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

New tool aims to curb overtreatment in Low-Risk thyroid cancer

NCT ID NCT06073223

Knowledge-focused Sponsor: University of Michigan Rogel Cancer Center Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 2 times

Summary

This pilot study tested a tool called CQUPLE, designed to help patients with low-risk thyroid cancer understand their treatment options and avoid overtreatment. Fifty patients were split into two groups: one received the CQUPLE decision aid and question list, while the other got usual care. The study measured how acceptable and feasible the tool was for patients and doctors.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
CQUPLE intervention (decision aid chart and question prompt list)
What this could lead to
If successful, this tool could help patients with low-risk thyroid cancer make more informed choices and reduce unnecessary surgeries.
What could go wrong
This is a small pilot study with only 50 participants, so results may not apply to everyone. The tool's effectiveness is still unproven.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

50 people

The number who actually took part.

Started

Sep 2023

Finished

Dec 2025

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 to 80 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Age 18 to 80 years * Low risk papillary thyroid cancer or highly suspicious for cancer * Low risk papillary thyroid cancer * cT1-2: Tumor size 4 cm or smaller and limited to the thyroid on ultrasound * cN0: No evidence of lymph node metastasis on ultrasound * cM0: No evidence of distant metastasis on imaging * Highly suspicious for cancer * Cytology meeting Bethesda V or Bethesday III or IV with molecular testing indicating a 70% risk of greater of thyroid cancer * Nodule size 4 cm and smaller * Limited to the thyroid on ultrasound * No evidence of suspicious lymph nodes * No evidence of thyroid cancer outside of the neck * Referred for surgical consultation. Exclusion Criteria: * History of previous thyroid cancer or thyroid surgery and parathyroid surgery * Non-English speaking * Deaf Subject Selection (for Surgeons) Surgeon Inclusion Criteria * Performs at least one thyroid surgery annually on adults * Credentialed at Michigan Medicine Surgeon Exclusion Criteria * None

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Low risk papillary thyroid cancer are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

thyroid cancer thyroid gland papillary carcinoma Thyroid Neoplasms

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Thyroid cancer

Contacts and locations

Locations

  • The University of Michigan Cancer Center

    Ann Arbor, Michigan, 48109, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.